Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and lymphokine-activated killer cells has been demonstrated to mediate regression of tumors in murine models and in selected patients with advanced cancer. Improved methods for monitoring immune cell traffic, particularly to sites of tumor, are needed to elucidate mechanisms of antitumor activity and optimize treatment protocols. Traditional cell tracking methods such as fluorescent protein labeling and radiolabeling using 111In, 125I, or 51Cr are limited by isotope half-life, leakage or transfer of label from immune cells, and toxicity or altered cell function caused by the labeling process. Labeling with genetic markers allows long-term cell tracking but is laborious to perform and difficult to quantitate. We have used two recently described lipophilic cell tracking compounds (PKH26 and 125I-PKH95) which stably partition into lipid regions of the cell membrane to track immune cells in vivo. Concentrations of each tracking compound which had no adverse effects were determined for a variety of murine TIL and lymphokine-activated killer cell functions. Viability was unimpaired at labeling concentrations of up to 5 microM for PKH95 and 20 microM for PKH26. TIL proliferation was unaltered by labeling with up to 5 microM PKH95, 20 microM PKH26, or a combination of 15 microM PKH26 and 5 microM PKH95. In vivo cytotoxic effector function and in vivo therapeutic efficacy of lymphokine-activated killer cells and TIL were also unimpaired by labeling with 20 microM PKH26 or 1 microM 125I-PKH95. Subsequent studies in an adoptive transfer immunotherapy model used 125I-PKH95 to track the biodistribution of TIL in tumor and in non-tumor-bearing animals and PKH26 fluorescence to monitor microdistribution within tissues and distinguish TIL from host T-cells. The results suggest that differential accumulation, selective retention, or proliferation at the tumor site cannot account for the observed pattern of therapeutic efficacy. We hypothesize that a minimum number of TIL must reach the tumor site in order to achieve a demonstrable therapeutic effect.
Wallace
P K
PK
Zynaxis Cell Science, Inc., Malvern, Pennsylvania 19355.
Palmer
L D
LD
Perry-Lalley
D
D
Bolton
E S
ES
Alexander
R B
RB
Horan
P K
PK
Yang
J C
JC
Muirhead
K A
KA
D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D005260:Female; D005434:Flow Cytometry; D005456:Fluorescent Dyes / Q000493:pharmacokinetics / Q000494:pharmacology; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007457:Iodine Radioisotopes; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D008168:Lung / Q000378:metabolism; D008175:Lung Neoplasms / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000628:therapy; D009930:Organic Chemicals; D014018:Tissue Distribution
D005456:Fluorescent Dyes; D007457:Iodine Radioisotopes; D009930:Organic Chemicals; C070080:PKH 26; C070059:PKH 95